Bildkälla: Stockfoto

Cantargia: Novartis Fails to Meet Endpoints in CANOPY-1 - Redeye

Redeye discusses Novartis' top-line results from CANOPY-1. We have a neutral stance on the news as it pertains to Cantargia.

Redeye discusses Novartis' top-line results from CANOPY-1. We have a neutral stance on the news as it pertains to Cantargia.
Börsvärldens nyhetsbrev
ANNONSER